Viyash Scientific Expands to Italy with BioForLife Acquisition

Total Consideration: EUR 16.975 million
Cash at Closing: EUR 15.0 million

Reader Takeaway: Strategic expansion into the Italian companion animal market with a proven distribution platform, offset by regulatory hurdles.

What just happened

Viyash Scientific, through its Irish step-down subsidiary Alivira Animal Health Limited, has agreed to acquire 100% of BioForLife Italia s.r.l., based in Milan, Italy. The total transaction value is EUR 16.975 million, comprising EUR 15.0 million in cash at closing and EUR 1.975 million as deferred consideration.

BioForLife Italia primarily focuses on the marketing and distribution of companion animal health products, including medicines, nutraceuticals, and testing kits.

Why this matters

This acquisition is a strategic move by Viyash Scientific to strengthen its position in the European companion animal segment. It allows the company to utilize BioForLife Italia's established front-end platform, customer reach, and product portfolio to drive growth in the European market.

The backstory

Viyash Scientific is involved in animal health products. BioForLife Italia has shown consistent growth, with annual sales projected to increase from EUR 7.1 million in CY 2023 to EUR 9.0 million in CY 2025.

What changes now

The transaction is expected to close within three months, subject to customary conditions and regulatory approvals, including under Italy's Golden Power Laws. The deferred payment of EUR 1.975 million will be settled within 12 months post-closing.

Risks to watch

Key risks include the fulfillment of conditions precedent and obtaining necessary approvals under the Italian Golden Power Laws. The success of integration and leveraging BioForLife's platform will also be crucial.

Peer comparison

This acquisition represents a multiple of approximately 1.88 times BioForLife's projected CY 2025 revenue. Investors can compare this valuation to similar transactions in the European animal health market.

Context metrics (time-bound)

BioForLife Italia's annual sales are projected to grow from EUR 7.1 million in CY 2023 to EUR 8.3 million in CY 2024 and EUR 9.0 million in CY 2025.

What to track next

Investors should monitor the progress of the regulatory approvals, the completion of the acquisition within the projected timeline, and how Viyash Scientific integrates and leverages BioForLife's operations to achieve its European expansion goals.